ONGLYZA™ is a treatment for patients with type 2 diabetes that has been
developed by an alliance between AstraZeneca and Bristol-Myers Squibb.
ONGLYZA is one of a class of compounds called DPP-4 inhibitors – known as gliptins - that work by enhancing the action of natural hormones in the body called incretins. Incretins decrease elevated blood sugar levels (glucose) by increasing the body’s utilization of sugar, mainly through increasing insulin secretion from the pancreas, and by reducing the liver’s production of glucose.For Summary of Product Characteristics and Patient Information Leaflet click this link
Approval ID: 155,827.011
Date of preparation: June 2014